News – Page 126 – Endpoints News

Biogen CEO sees Alzheimer's drug on right path despite tiny sales, will keep biosimilars business

10 months ago

With $144M Series B, Outpace Bio beats funding goal for solid tumor cell therapies

10 months ago

AbbVie closes $8.7B Cerevel deal in bid to compete with Bristol Myers in schizophrenia

10 months ago

VC firm venBio secures $528M for ‘extremely selective’ fifth fund after recent IPOs, M&A exits

10 months ago

Updated: Jim Wilson to step down from gene therapy post at UPenn, will form two new companies

10 months ago

US sales for Merck KGaA’s Bavencio impacted by Padcev/Keytruda momentum in bladder cancer

10 months ago

It took more than two decades for MDMA to reach the FDA. In two months, its prospects cracked. What happens next?

10 months ago

Rare disease biotech raises $47M Series C, plans for Phase 2 trial

10 months ago

Updated: Eli Lilly’s tirzepatide reduces risk of heart failure outcomes in Phase 3 study

10 months ago

Updated: Otsuka buys out small molecule drug discovery startup Jnana and its rare disease pill for $800M cash

10 months ago

Sage changes main endpoint in Huntington's study months ahead of readout

10 months ago

Teladoc records $790M charge, withdraws outlook as mental health business loses users

10 months ago

After norovirus vaccine's trial failure, HilleVax lays off 40% of staff

10 months ago

Judge rejects Novo Nordisk's IRA case as pricing negotiations conclude

10 months ago

ALX Oncology continues its CD47 quest, revealing Phase 2 gastric cancer data

10 months ago

Humana is still struggling with high medical costs as new CEO Jim Rechtin takes over

10 months ago

Teva factored IRA's next round of negotiations into its growth plans

10 months ago

Sanofi sues Sarepta, alleging that Duchenne treatment Elevidys infringes on AAV patents

10 months ago

Takeda defends Alzheimer's pact, TYK2 potential as restructuring is in 'full swing'

10 months ago

FDA questions Zevra’s resubmitted data for rare disease drug ahead of adcomm

10 months ago

Updated: Eisai says Alzheimer's drug keeps working after three years. But weaknesses in study raise questions

10 months ago

Ideaya and Biocytogen ink $400M+ deal; Daiichi spends more on superstar ADCs

10 months ago

MacroGenics stops further dosing in Phase 2 prostate cancer drug trial

10 months ago

As Amgen pursues GIP antagonism, a Novo Holdings-backed biotech does the same, boosting its Series A

10 months ago

First page Previous page 123 124 125126127 128 129 Next page Last page